A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Clinical trial NCT04188379 · COMPLETED

Trial details

NCT number: NCT04188379
Sponsor: argenx
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Immune Thrombocytopenia

Start date: 2019-12-16
Primary completion: 2022-02-03
Enrollment: 131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.